Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIPICOL: RECIST 1.1 vs iRECIST in nivolumab + ipilimumab for dMMR/MSI metastatic colorectal cancer
2017-002442-72Phase 2Active
- Sponsor
- GERCOR
- Start
- Oct 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in metastatic colon cancer (mCRC) and colorectal cancer (CRC), sponsored by GERCOR. Primary endpoint: Disease control rate at 12 weeks (RECIST 1.1 vs iRECIST). Started Oct 2017; status: active.
02
Drugs
nivolumabipilimumab
03
Conditions
metastatic colon cancer (mCRC)colorectal cancer (CRC)
Beyond the preview
Go deeper on 2017-002442-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002442-72.